October 2020 Type C meeting planned with the FDA for NTM-006, an oral new chemical entity with a novel mechanism of action targeting neuropathic pain
Based on recent FDA guidance letter, Neumentum believes there is clear understanding of the regulatory path forward for NTM-001, a Phase 3-ready potent NSAID targeting moderately severe post-surgical pain
Neumentum remains committed to transforming the way pain is treated – without opioids
PALO ALTO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today provided a corporate update on notable business accomplishments and priorities for its two lead product candidates NTM-006 and NTM-001.
“Our broad portfolio of assets targeting multiple types of acute and chronic pain through novel and known mechanisms are well positioned to address the sizeable pain market and ongoing opioid crisis,” said Scott Shively, chief executive officer of Neumentum. “We continue to make significant progress with NTM-006, a new chemical entity non-opioid, non-NSAID analgesic candidate under development for neuropathic pain and other moderate-to-severe chronic pain conditions, and NTM-001, a 24-hour continuously infused non-opioid analgesic (Toradol PMB), which is a Phase 3-ready intravenous product for moderately severe acute and particularly post-surgical pain.”
Business Highlights and Recent Developments
About Neumentum: Addressing a National Health Emergency
Opioid use is considered a critical public health concern in the US. In 2018, 9.9 million people over age of 12 reported misusing prescription opioid pain relieversi. More than 70 million surgical procedures are performed in the U.S. annually and postsurgical pain is routinely treated with opioid analgesics.
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids. Neumentum’s NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids. Additionally, NTM-006, a product that is neither an opioid nor a nonsteroidal anti-inflammatory drug (NSAID), has completed a positive Phase 2A clinical study in moderate to severe acute pain. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.
INVESTOR CONTACT:
Scott Shively
CEO & Co-founder
scottshively@neumentum.com
(833) NEUPAIN
MEDIA CONTACT:
Surabhi Verma
Westwicke, an ICR company
Surabhi.Verma@westwicke.com
646-677-1825
[i] SAMSHA, Key Substance Use and Mental Health Indicators in the US: Results from the 2018 National Survey on Drug Use and Health. P13, Fig 10.